Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C4HG
|
|||
| Former ID |
DAP000797
|
|||
| Drug Name |
Levosimendan
|
|||
| Synonyms |
Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Approved | [1] | |
| Heart failure [ICD-11: BD10-BD13] | Phase 4 | [2] | ||
| Cardiac output syndrome [ICD-11: BC43] | Phase 3 | [3] | ||
| Pulmonary hypertension [ICD-11: BB01; ICD-10: I27, I27.0; ICD-9: 416] | Phase 2 | [3] | ||
| Therapeutic Class |
Cardiotonic Agents
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12N6O
|
|||
| Canonical SMILES |
CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
|
|||
| InChI |
1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1
|
|||
| InChIKey |
WHXMKTBCFHIYNQ-SECBINFHSA-N
|
|||
| CAS Number |
CAS 141505-33-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10047801, 12014745, 14750877, 14848712, 36077662, 46507149, 47206545, 49830764, 50021023, 50329902, 53787445, 53801208, 57352771, 71824917, 92713457, 111635103, 118313757, 121362207, 123055572, 126629835, 126656038, 126669841, 131298709, 134338082, 135018142, 136949639, 137003253, 143344346, 144076122, 144205744, 152034633, 160685135, 160964261, 164831535, 165235325, 170466128, 170466129, 174006271, 175435414, 175610931, 196111104, 198945531, 198949793, 210275075, 210280713, 223658996, 223704586, 224600906, 226461901, 252359301
|
|||
| ChEBI ID |
CHEBI:50567
|
|||
| ADReCS Drug ID | BADD_D01284 | |||
| SuperDrug ATC ID |
C01CX08
|
|||
| SuperDrug CAS ID |
cas=141505331
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4] | |||
| Metabolic Reaction | Reduction | |||
| Description | Levosimendan can be metabolized by gut microbiota through reduction. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Troponin C (TN-C) | Target Info | Stimulator | [5], [6] |
| KEGG Pathway | Calcium signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Dilated cardiomyopathy | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Striated Muscle Contraction | |||
| WikiPathways | Striated Muscle Contraction | |||
| Muscle contraction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. | |||
| REF 2 | ClinicalTrials.gov (NCT04705337) Levosimendan In Ambulatory Heart Failure Patients (LEIA-HF). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | The metabolic effect of gut microbiota on drugs. Drug Metab Rev. 2020 Feb;52(1):139-156. | |||
| REF 5 | Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30. | |||
| REF 6 | Levosimendan does not improve survival time in a rat model of verapamil toxicity. J Med Toxicol. 2009 Mar;5(1):3-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.